Santhera Reports Positive Phase III Clinical Trial Results for Raxone®/Cantana® (idebenone) for the Treatment of Duchenne Muscular Dystrophy

Press Release: Santhera’s Positive Phase III Trial (DELOS) in Patients with Duchenne Muscular Dystrophy Published in The Lancet

“This is welcome news for our community,” said MDA Senior Vice President and Scientific Program Director Grace Pavlath, Ph.D. “The need for effective DMD therapies is urgent, and we look forward to the possibility that idebenone may be approved as a treatment that will benefit our families living with DMD.”

About MDA

The Muscular Dystrophy Association is the world’s leading nonprofit health agency dedicated to saving and improving the lives of people with muscle disease, including muscular dystrophy, amyotrophic lateral sclerosis (ALS) and other neuromuscular diseases. It does so by funding worldwide research to find treatments and cures; by providing comprehensive health care services and support to MDA families nationwide; and by rallying communities to fight back through advocacy, fundraising and local engagement.

Visit mda.org and follow us at facebook.com/MDAnational and @MDAnews. Learn more about MDA’s mission by watching this video.

Roxan Olivas
MDA Vice President  — Public Relations & Community Programs
(520) 529-5317
rolivas@mdausa.org